Sertraline (HCl)

Sertraline (HCl) is oral antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type. Sertraline (HCl) is similar to fluoxetine and paroxetine. Sertralin has one active metabolite and the lowest potential for drug interactions involving CYP2D6 (cytochrome P-450 isoenzyme 2D6) of the SSRIs. Sertraline has also been used in the treatment of obsessive-compulsive disorder (OCD). Sertraline was approved by the FDA in December 1991 for the treatment of major depression. In October 1996, it was approved for treatment of OCD. Sertraline (HCl) is believed that sertraline and related agents inhibit reuptake of serotonin at the neuronal membrane, and potentiate serotonin (5-HT) in the CNS.


Adult Dose
Dose: 50 mg
Single Dose: 50 (50)
Frequency: 24 hourly
Route: PO
Instructions: Initially for 2 Weeks
Neonatal
Paedriatic
Dose: Safety not established
Single Dose:
Frequency:
Route:
Instructions:
Characteristics
Sertraline is the derivative of Sertraline (HCl). It is of Synthetic origin and belongs to Naphthalene Amine. It belongs to Psychotherapeutic Drugs and Antidepressant pharmacological group.The Molecular Weight of Sertraline (HCl) is 342.70.
Contraindications
Sertraline (HCl)
Effects
The symptomatic adverse reactions produced by Sertraline (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Diarrhea, Palpitation, Insomnia, SomnolenceX, Xerostomia, Ejaculatory disturbances.
Indications
Sertraline (HCl) is primarily indicated in conditions like Depression, Depressive illness, Obsessive-compulsive disorders, Panic attack, Post traumatic stress disorder.
Interactions
Sertraline (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdinazolamAlcoholClozapineSertraline enhances the serum level of clozapine by inhibiting its hepatic metabolism result in increased toxicity.ModerateClosely monitor for change in efficacy and safety. Adjust dose if ecessary.FurazolidoneRisk of serotonin syndrome i.e inhibition of serotonin metabolism by furazolidine due to additive effect which may be fatal because of hyperstimulation of 5HT1 A receptor results in enhance sertraline pharmacologic activity. MajorThis combination should be avoided or give a gap of atleast 2 weeks before or after use of any of these drugs.Metoprolol (Tartrate)Sertraline may potentiate the pharmacological effect of metoprolol by inhibiting metabolic clearence result in development of bradycardia, hypotension, and complete heart block.ModerateClosely monitor the cardiac function of patient and adjust the dose of metoprolol accordingly.NaratriptanConcurrent use is not recommended, but dosages should be adjusted if concurrent use is required.PhenelzineSumatriptanConcomitant use of these drugs potentiates the risk of serotonin syndrome due to hyperstimulation of brain stem 5-HT1A receptor. MajorClosely monitor the sign and symptoms of serotonin syndromeVilazodonesertraline is MAOIs ( mono amino oxidase inhibitor) and fatal risks are associated with itMAOIs are Contraindicated with VilazodoneVortioxetineincreases the toxicity of vortioxetineuse alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Elevations of SGPT and SGOT Elevation in ALT or ASTIncreased serum triglycerides
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store Below 40°C. Protect from Sunlight and Heat.
Warnings
Sertraline should be used only if clearly needed during pregnancy. It should be used with caution in patients with any pre-existing kidney disease or liver disease,history of seizures or if have any allergy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.